Accelerating Medicines, Together

1© Copyright 2024 Certara, L.P. All rights reserved.
© Copyright 2024 Certara, L.P. All rights reserved.

Disclaimer
Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the“Company,” “Certara,” “we,” “us,” and “our” refer to Certara, Inc. and its consolidated subsidiaries.
Trademarks and Service Marks
The Certara design logo, “Certara,” and our other registered or common law trademarks, service marks or trade names appearing in this presentation are our property. Solely for convenience, our trademarks, tradenames, and service marks referred to in this presentation appear
without the registered mark or trademark symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, tradenames, and service marks. This presentation contains additional
trademarks, tradenames, and service marks of other companies that are the property of their respective owners. We do not intend our use or display of other companies’ trademarks, trade names or service marks to imply relationships with, or endorsement or sponsorship of us by,these other companies.
Forward-Looking Statements
This presentation includes forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, that reflect the Company’s current views with respect to, among other things, the Company’s operations and financial
performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,”“intend,” “project,” “forecast,” “estimates,” “targets,” “projections,” “should,” “could,” “would,” “may,” “might,” “will,” and other similar expressions. We base these forward-looking statements or projections on our current expectations, plans and assumptions, which we have madein light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at the time. The forward-looking statements are based on our beliefs,
assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. Actual results may differ materially from thosedescribed in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company’s ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed
biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession, currency exchange fluctuation
and adverse developments in the financial services industry; trends in research and development (R&D) spending; delays or cancellations in projects due to supply chain interruptions or disruptions or delays to pipeline development and clinical trials experienced by our customers,
and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings and reports, including the Annual Report on Form 10-K filed with the SEC on February
29, 2024 and subsequent reports. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results todiffer materially from those contained in any forward-looking statements we may make. Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and is expressly qualified in its entirety by the cautionary statements included inthis presentation. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable laws. You should not place undue reliance on ourforward-looking statements.
Non-GAAP Financial Information
This presentation contains “non-GAAP measures” that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting
principles (“GAAP”). Specifically, we may make use of the non-GAAP financial measures adjusted EBITDA, adjusted EBITDA margin, [adjusted net income (loss), adjusted diluted earnings per share (“EPS), and constant currency (“CC”) revenue, which are not recognized terms under
GAAP and should not be considered as alternatives to net income (loss), GAAP EPS, or GAAP revenue as measures of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. These
non-GAAP measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to othersimilarly titled measures of other companies and can differ significantly from company to company.
Adjusted EBITDA represents net income (loss) excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, acquisition and integration expense and other items notindicative of our ongoing operating performance. Adjusted EBITDA margin represents adjusted EBITDA divided by revenue. [Adjusted net income] and adjusted diluted EPS exclude the effect of the same items noted above with respect to adjusted EBITDA from GAAP net income (loss)
and GAAP EPS, respectively, as well as adjust the provision for income taxes for such charges. CC revenue excludes the effects of foreign currency exchange rate fluctuations by assuming constant foreign currency exchange rates used for translation. Current periods revenue reported
in currencies other than U.S. dollars are converted into U.S. dollars at the average exchange rates in effect for the comparable prior periods. You should refer to the appendix at the end of this document for a reconciliation of these non-GAAP measures in specific periods to their mostdirectly comparable financial measures calculated and presented in accordance with GAAP for those periods.

Management uses various financial metrics, including total revenues, income from operations, net income, CC revenue and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company’s business, to evaluate the effectivenessof its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures forperiod-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance. Management believes that these metrics are helpful to investors, analysts, and other interested
parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance. In
addition, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We use CC revenue to evaluate theunderlying performance of the business, and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance. In evaluating adjusted EBITDA, [adjusted net income (loss)] adjusted diluted EPS, and CC
revenue, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.
2© Copyright 2024 Certara, L.P. All rights reserved.

Our Mission

We accelerate medicines to patientsusing biosimulation software, technology and services
to transform traditional drug discovery and development.

3© Copyright 2024 Certara, L.P. All rights reserved.

Certara at a Glance
BUSINESS(1)20+ Year
History of innovation~1,400 Employees
430+with Ph.D.s,
Pharm.D.s and M.D.s

20 Acquisitions
Track record of accretive,complementaryacquisitions

END-TO-END PLATFORM

Software• Biosimulation• Regulatory & compliance• Market access

CUSTOMERS(3)2Q 2024 FINANCIALS~2,400
Customers across
66 countries$93.3M Revenue

Technology-Driven Services• Drug discovery &development withbiosimulation• Regulatory science• Market access

10+ Year
Average tenure
for top 30 customers

389 customers with
ACV > $100,000$26.3M
Reported Adjusted
EBITDA(5)PY $32.4M$14B TAM growing at
8-17% CAGR(2)63 customers with
ACV > $1M

28% Adjusted EBITDA
Margin(5)(1) As of 12/31/2023(2) Market research reports from Grand View and SpendEdge; as of 2024
(3) Customer data as of 12/31/2023(4) See Appendix for reconciliation of GAAP revenue to constant currency (non-GAAP revenue)(5) See Appendix for reconciliation of net income (loss) to adjusted EBITDA

4

3% GAAP YoY Growth
3% CC YoY Growth(4)© Copyright 2024 Certara, L.P. All rights reserved.

Net Income ($12.6M)
PY $4.7M

Biosimulation is transforming traditional drug R&D
Traditional R&D Pain Points

Benefits of Biosimulation• On average, it takes more than
10 years and $2B to bring a drug to market1• In silico trials can replace human clinical trials incertain cases, saving significant time andmoney• The probability of success of compounds
entering Phase I trials is only 7%2, and even in
Phase III, just 53%3 of drugs reach the market• Biosimulation helps to increase probability ofsuccess in human clinical trials, the mostexpensive part of drug development• ~70% of drugs that failed in Phase II or Phase
III trials4 failed due to safety and efficacy issues• Biosimulation helps to optimize dosing fordifferent populations for enhanced safety andefficacy

Biosimulation can deliver significant time and cost savings in drug discovery and development
1. Biopharmaceutical Research and Development: The Process Behind New Medicines. www.PhRMA.org, January 2012, Washington, US http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf
2. Dowden, H. et al. Trends in clinical success rates and therapeutic focus. Nature Reviews Drug Discovery 18, 495-496 (2019)
3. EvaluatePharma. World Preview. 2020
4. Harrison, R. Phase II and phase III failures: 2013 – 2015. Nat Rev Drug Discov 15, 817-818 (2016). https://doi.org/10.1038/nrd.2017.184

5© Copyright 2024 Certara, L.P. All rights reserved.

Biosimulation utilizes virtual patients to conduct in silico trials
Biosimulation is the computer-aided mathematical modeling of biological processes and systems to simulate andpredict how the body affects the drug and how the drug affects the body
Simcyp Advanced Models for 10 Organs

Biosimulation Software ApplicationsFirst-in-Human
DosingDrug-Drug
Interactions

Clinical Study Design

Pediatric Dosing

Bioequivalence

Formulation

Renal Impairment

Hepatic Impairment

Reduced Cardiac
OutputFood EffectWe have created 29 different virtual patient populations and mathematical models for 10 organs
6© Copyright 2024 Certara, L.P. All rights reserved.

Growing industry and regulatory adoption of biosimulation
Number of Scientific Publications
on Biosimulation~8,000

Increased Incorporation of Biosimulation withFDA Guidance2
1730+ FDA Guidances to Date

Pediatricrare diseases
Drug-druginteraction
PBPK
Biosimilars~2,000

5

3

PK Modeling

PBPK

PopPK
Dose-response<2000

1. Science Direct search for publications by key search terms
2. Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations. Wang et al. Clinical Pharmacology and Therapeutics, April 20197

© Copyright 2024 Certara, L.P. All rights reserved.

6

Hypertension

Ulcerative
colitis Pediatric

Pediatric
Multi- regional
Renal
Renal
HIV
HIV
impairment
AnimalAnimal impairmentclinical trials
Hepatic PopPKQT interval
QT intervalHepatic
impairment
impairment
Dose-response
prolongation
prolongation
2000 - 20102011 - 20152016 - 2020

Simcyp software has informed 300+ labels for 100 novel drug approvals

We believe that our customers would have faced millions in additional costs and significant launch delays
had they conducted human clinical trials for these drug label claims
8© Copyright 2024 Certara, L.P. All rights reserved.

Blue chip customer base spanning large biopharma and biotech
Select Customers

Number of FDA Approvals Since 2014

90% of novel drug
approvals were achieved byour customers*Excludes diagnostics
Orphan designation applies across therapeutic areas

We have nearly 2,400 customers worldwide across 66 countries, including
38 of the top 40 biopharmaceutical companies by R&D spend in 2022
9

© Copyright 2024 Certara, L.P. All rights reserved.

The Certara End-to-End Platform
Discovery

Preclinical

ClinicalPost-Approval

Across All Drug Types (NDAs and BLAs)
SoftwareBiosimulation Software Platforms
37% ofrevenue¹

Regulatory and Compliance Software
Market Access Software

Tech-driven
Services

Drug Discovery and Development Services with Biosimulation
63% ofrevenue¹

Regulatory Science
Market Access

For over 20 years, we have purpose-built and invested in our proprietary
end-to-end platform with strategic acquisitions and innovation
1. As of 12/31/2023

10© Copyright 2024 Certara, L.P. All rights reserved.

Our end markets are large and growing$14B+
TAM Today CAGR
Biosimulation$4.0B+~17%

Regulatory Science $8.2B+~8%Market Access~12%$1.6B+$19B+
2027 TAM• Drastic need for digital transformation in $212B
biopharma R&D market1• Industry is in paradigm shift, with biosimulation
adoption accelerating and increasing acceptancefrom regulatory agencies• Technology and analytics-driven improvements
continue to grow exponentially in Life Sciences

1. As of 2024
Sources: Grand View Research, SpendEdge

We use biosimulation and technology throughout R&D to reduce costs and improve outcomes11© Copyright 2024 Certara, L.P. All rights reserved.

Biosimulation TAM Segmentation
Biosimulation TAM$4.0B
Biosimulation Software~50%

Biosimulation Services~50%

Scientists at global pharmaceutical companies,
mid-tier pharma, biotechs and CROs

Drug R&D programs(illustrative examples)

Certara Solutions

Drug Discovery~45%• Quantitative Systems
Pharmacology (QSP)o Immuno-oncology QSPo Immunogenicity QSP• Discovery Informatics
o D360 Software

Drug Development
~55%

Drug
Discovery~20%• PBPK1
o Simcyp Simulator• PK/PD2o Phoenix Software• PBPK Consulting• QSP• PK/PD analysis
Consulting• Model-based meta-analysis• Model-based meta-analysis
o CODEx Databases

1 Physiologically-based pharmacokinetic (PBPK)
2 Pharmacokinetic/pharmacodynamic (PK/PD)

12Drug Development~80%© Copyright 2024 Certara, L.P. All rights reserved.

Differentiated scientific and technology expertise

Key Differentiators

SoftwareTech-driven Services✓ Industry standard built over 20 years✓ Scalable service model powered by proprietary technology✓ Adopted by 23 global regulatory agencies✓ High net revenue repeat rate of 96% in 2023

✓ Embedded in customers’ R&D processes – 105%+ net retention
rate(1)✓ Integrated services with 90% of our top 50 customers using
both biosimulation solutions and regulatory & access services✓ Validated by 34k+ scientific publications✓ Renowned for key opinion leadership✓ Used by ~400 academic institutions✓ Depth and breadth of experience across every therapeutic areaand modality✓ 10+ year average tenure for top 30 customers

Our differentiated strengths enable us to win new customers and projects(1) Our net retention rates measure the percentage of recurring revenue that is retained from existing software customers over a specific time period of time, inclusive of price increases and expansion,for businesses that have been owned for greater than 12 months
13© Copyright 2024 Certara, L.P. All rights reserved.

Deeply experienced leadership team and global talent footprint~420

Scientists
North America~230

Regulatory Experts~690

Europe~510

Asia Pac
~200

~100

Market Access Specialists~220

Software Developers &Technologists

Of our ~1,400 employees, 430+ hold PhD, PharmD, or MD degrees
14© Copyright 2024 Certara, L.P. All rights reserved.

Certara’s Industry-Standard Software
Biosimulation

SimcypLeading mechanistic biosimulation
platform used to predict how drugs work,without human or animal studies

Regulatory & Market AccessPhoenix
Industry-leading software for PK/PD,
toxico-kinetic, and non-compartmental
analyses – required for regulatory
submissions

GlobalSubmit

BaseCase

Synchrogenix
WriterIntegrated informatics platform with
self-service access and analytics to
help manage discovery projects

D360

55 proprietary databases for metaanalysis of a new drug’s safety and
CODEx efficacy relative to other products

Cloud-based software to manage
regulatory compliance andsubmissions and valuecommunication

Certara Integral Repository

Our industry-leading software is adopted by more than 57,000 users worldwide across 66 countries
All statistics are as of 12/31/2023 unless noted15© Copyright 2024 Certara, L.P. All rights reserved.

Certara.AI Platform
Secure, flexible platform for deploying life science specific GPTs across organizational data
✓ Purpose-Built GPTs: Trained specifically on biomedical data, GPTs within

Certara.AI

App Suite

Certara.AI are purpose-built to understand scientific concepts enabling highly
specific, validated responses.

✓ GPT Referencing: By securely connecting to customer data, Certara.AI provides
direct access to internal documents and files to enable referencing of GPT
responses.

✓ Up to Date Information: Indexes data in real-time, ensuring GPTs have access toConnectivity Framework

up-to-date insights required for life science analytics.

✓ Scalability: Has a scalable architecture allowing expansion to new data
environments and deployment to new GPT models without interfering withexisting workflows.

✓ Trained on Customer Data: GPT models within Certara.AI train on customer data,
allowing for organization specific GPT models that understand use cases andterminology.

✓ Pre-Analyzed Library of Public Life Science Content: Features a library of over 60

Client Documents

million life science research documents.

ClientDatabases

Reference Data(>60 Million Docs)

Certara.AI is being integrated across Certara’s end-to-end product suite in discovery, clinical, and regulatory
16© Copyright 2024 Certara, L.P. All rights reserved.

Certara’s platform is built to meet clients where they are
Customer Journey
Tangible cost andtime savings
drive renewal
and retention

Innovate$

Cross-Sell

Deeper Adoption

First Landing

Large Biopharma

BiotechGenerates new biosimulation use
case for novel therapy

Retains services for expansionof indications

Adopts regulatory
software to aid submission

Partners to develop and executeon regulatory strategy

Increases licenses to expand use
across drug programs; adopts
additional biosimulation modules

Licenses software for additional
development projects

Licenses biosimulation
softwareUses services to conductbiosimulation project

Time
17

© Copyright 2024 Certara, L.P. All rights reserved.

Our R&D framework advances innovation in biosimulation
•
•
•
•

•
•
•

Consortia collaboration
User group meetings
Scientific Advisory Board
1,000+ scientific customer
projects per year

Collaboration with 120+academic institutions
5,000+ peer-reviewed articles
34,000 Google Scholar citations

Scientific
Research

Customer
Centricity

Regulatory
Alignment

Innovation

Data
Collection& Curation

•
•
•

•
•
•

Regulatory guidances
Regulatory workshops
Regulatory meetings forcustomer programs

29 virtual populations
18,000+ peer-reviewed manuscripts
8,000+ studies in our databases

We have a regular cadence of incremental and breakthrough innovations
with new software applications and updates
18© Copyright 2024 Certara, L.P. All rights reserved.

Our proven growth strategy
PeopleGlobalExpansion
M&A
Land andExpandInnovationv

Technology
leader with 105%+
net retention rate19v

Significant whitespace to expand
with customers
and add new onesv

20 successful
strategic
acquisitions, 13
with software© Copyright 2024 Certara, L.P. All rights reserved.

vv

An employer ofchoice, attracting
leading experts

Track record of
mid-teens topline growthwith EBITDA margins in
mid- to high-30s

Long history of innovation driven by investment in our platform
Product Innovation
Pre-clinical safety
score

Phoenix v1.3

D360
incorporating
biologics

Virtual monkey
for in silico
animal testing

Simcyp Cardiac
Safety Simulator

Immuno-ocology
QSP Consortium

Immunogenicity
QSP Consortium

Phoenix PK/PD
CoEs in China andJapan

Covidpharmacology.com
Certara Integral
Data repository

Simcyp PBPK
Simulator Version
21

25+ COVID-19
Programs

Reg. Mechanistic
modeling
workshops

2012 → 20192020

Private Equity Owned

2021

Immunogenicity(IG), Immunooncology (IO) and
VaccineSimulator
Simcyp Discovery
Simulator

Simcyp PBPK
Simulator Version
22
AI enhancements
across productportfolio
Simcyp
Biopharmaceutics

Pinnacle 21 Data
Exchange Module

Phoenix Hosted

2022

2023

Public Company
PIRANADIDB®

IN SILICO

BIOSCIENCES

Well-positioned to continue delivering growth through organic and inorganic opportunities
20© Copyright 2024 Certara, L.P. All rights reserved.

2024

Certara Financial Highlights
Predictable bookings drive substantial revenue growthHighly recurring revenue driven by strong retention rates supports significant
visibility

Robust margins with attractive free cash flow conversion

Investment in platform to drive future growth opportunities

Long term potential for accelerated adoption of biosimulation solutions

21© Copyright 2024 Certara, L.P. All rights reserved.

Our Business Models
SoftwareProducts••••

SimcypPhoenix
D360
CODEx

•
•
•
•

GlobalSubmit
BaseCase
Pinnacle 21
IntegralTech-Driven Services• Biosimulation• Market Access• Regulatory Science

Contract Type

Individual or bundled licenses depending
on customer

Master Services Agreement or project
specific

Contract Term

1 – 3 years

Project and program dependent

Recurring
Revenue1

Net Retention Rate(2)109%

Net Revenue Repeat Rate96%

% of Revenue1

37%

63%

(1) Data as of 12/31/2023(2) Our net retention rates measure the percentage of recurring revenue that is retained from existing software customers over a specific time period of time, inclusive of price increases and expansion,for businesses that have been owned for greater than 12 months
22© Copyright 2024 Certara, L.P. All rights reserved.

Environmental, Social and Governance (ESG)
Certara Inaugural ESG Report
Issued April 2022•

Accelerating crucial medicines to patients•

Advancing scientific thought leadership and knowledge sharing•

Increasing engagement with employees

GENDER AND ETHNICALLY DIVERSE REPRESENTATION

23© Copyright 2024 Certara, L.P. All rights reserved.

We have a deeply experienced leadership team

24

William F. Feehery, PhD
Chief Executive Officer

John Gallagher
Chief Financial Officer

Leif E. Pedersen
President, Chief
Commercial Officer

Patrick F. Smith
President, Drug
Development Solutions

Robert Aspbury, PhD
President, Certara
Scientific Software

Max Kanevsky
Chief Technology Officer

Rona Anhalt
Chief Human Resources
Officer

Sheila Rocchio
Chief Marketing Officer

Ron DiSantis
SVP, Corporate
Development

Daniel Corcoran
General Counsel© Copyright 2024 Certara, L.P. All rights reserved.

Certara investment highlights
Attractive end markets growing in mid-teens driven by R&D efficiency demand and global adoption
Technology leader with highly predictable business model with 105%+ net retention rates
Deeply embedded scientific solutions at the core of R&D with ~2,400 customers
Significant opportunities to expand within customer base and add new customers worldwide
Proven track record of innovation and 20 successful strategic acquisitions
Long track record of growth and profitability with 35%+ EBITDA margins and strong free cash flow$

25

© Copyright 2024 Certara, L.P. All rights reserved.

Covering Analysts
Bank

AnalystBaird

Joe Vruwink

Bank of America

Michael Ryskin

Barclays

Luke Sergott

Jefferies

David Windley

JMP Securities

Constantine Davides

KeyBank

Scott Schoenhaus

Leerink

Michael Cherny

Morgan Stanley

Vikram Purohit

Stephens

Jeff Garro

UBS

Dan Leonard

William Blair

Max Smock26© Copyright 2024 Certara, L.P. All rights reserved.

Accelerating Medicines

27© Copyright 2024 Certara, L.P. All rights reserved.

Reconciliation of Net Income (Loss) to Adjusted EBITDA
THREE MONTHS ENDED

SIX MONTHS ENDED

JUNE 30JUNE 30,

2024

2023

2024

2023

( in thousands)

Net income (loss)(a)$(12,574)$4,706$(17,257)$6,064

Interest expense(a)

5,578

5,668

11,329

11,143

Interest income(a)(2,486)(2,210)(5,060)(3,564)(Benefit from) Provision for income taxes(a)

305

3,675

(446)

4,786

Depreciation and amortization expense(a)

451

361

883

772

16,146

13,17332,142

26,286

104

1,120

980

2,014

Equity-based compensation expense(b)

9,783

3,610

18,856

12,153

Change in fair value of contingent

2,783

1,298

5,661

2,559

Acquisition-related expenses(e)

1,073

692

2,787

1,884

—

55

—

157

2,753

—

2,753

—

183

—

183

—

2,163

—

2,214

—

Loss on disposal of fixed assets(j)

13

25

13

29

Executive recruiting expense(k)

43

200

423

396

$26,318$32,373$55,461$64,679

Intangible asset amortization(a)Currency (gain) loss(a)Integration expense(f)Transaction - related expenses (g)Severance expense(h)Reorganization expense(i)Adjusted EBITDA

28© Copyright 2024 Certara, L.P. All rights reserved.

28

Reconciliation of Revenues to the Revenues Adjusted for Constant Currency

29© Copyright 2024 Certara, L.P. All rights reserved.

Notes to Reconciliations(a) Represents amounts as determined under GAAP.
(b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in ourbusiness and an important part of our compensation strategy.
(c) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.
(d) Represents expense associated with remeasuring fair value of contingent consideration of business acquisition.
(e) Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.
(f) Represents integration costs related to post - acquisition integration activities.
(g) Represents costs associated with our public offerings that are not capitalized, as well as debt issuance costs that are not deferred or treated as a contra-liability directly deductedfrom the carrying value of the associated debt liability.
(h) Represents charges for severance provided to former executives.
(i) Represents expense related to reorganization, including legal entity reorganization and lease abandonment cost associated with the evaluation of our office space footprint(j) Represents the gain/loss related to disposal of fixed assets.
(k) Represents recruiting and relocation expenses related to hiring senior executives.
(l) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.
(m) Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding.

30© Copyright 2024 Certara, L.P. All rights reserved.

Accelerating Medicines, Together

31© Copyright 2024 Certara, L.P. All rights reserved.